Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2016 (2016), Article ID 5653862, 11 pages
http://dx.doi.org/10.1155/2016/5653862
Review Article

Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy

1Division of Hepatology and Liver Research, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Observatory, Western Cape 7925, South Africa
2Division of Rheumatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Observatory, Western Cape 7925, South Africa
3Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Western Cape 7925, South Africa
4Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Private Bag X169, Pretoria, Gauteng 0001, South Africa
5Department of Surgery, Faculty of Health Science, University of Cape Town and Groote Schuur Hospital, Observatory, Western Cape 7925, South Africa

Received 21 June 2016; Accepted 4 October 2016

Academic Editor: Cristina Magi-Galluzzi

Copyright © 2016 Mankgopo M. Kgatle et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. J. Fourie, A. McMaster, R. Mothilal, and K. I. Maart, “A phase IV clinical trial of patients with solid tumors receiving lenograstim as primary prophylaxis for chemotherapy-induced neutropenia, in a docetaxel-based regimen,” Journal of Cancer Research, vol. 2014, Article ID 684936, 7 pages, 2014. View at Publisher · View at Google Scholar
  2. G. Alleyne, A. Binagwaho, A. Haines et al., “Embedding non-communicable diseases in the post-2015 development agenda,” The Lancet, vol. 381, no. 9866, pp. 566–574, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Catalona, J. Richie, F. Ahmann et al., “In reply: re comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer receiver operating characteristic curves; re selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer receiver operating characteristic curves,” The Journal of Urology, vol. 154, pp. 1145–1146, 1995. View at Google Scholar
  5. M. J. Barry, “Screening for prostate cancer-the controversy that refuses to die,” New England Journal of Medicine, vol. 360, no. 13, pp. 1351–1354, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. B. A. Lipski, R. L. Garcia, and M. K. Brawer, “Prostatic intraepithelial neoplasia: significance and management,” Seminars in Urologic Oncology, vol. 14, no. 3, pp. 149–155, 1996. View at Google Scholar · View at Scopus
  7. J. I. Epstein, M. J. Zelefsky, D. D. Sjoberg et al., “A contemporary prostate cancer grading system: a validated alternative to the gleason score,” European Urology, vol. 69, pp. 428–435, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. A. O. Sartor, “Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space,” Journal of Hematology & Oncology, vol. 4, article 18, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. T. A. Skolarus, A. M. D. Wolf, N. L. Erb et al., “American Cancer Society prostate cancer survivorship care guidelines,” CA: Cancer Journal for Clinicians, vol. 64, no. 4, pp. 225–249, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Hieronymus, N. Schultz, A. Gopalan et al., “Copy number alteration burden predicts prostate cancer relapse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 30, pp. 11139–11144, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. E. D. Crawford, C. S. Higano, N. D. Shore, M. Hussain, and D. P. Petrylak, “Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies,” The Journal of Urology, vol. 194, no. 6, pp. 1537–1547, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Afshar-Oromieh, E. Avtzi, F. L. Giesel et al., “The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 42, no. 2, pp. 197–209, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. D. A. Silver, I. Pellicer, W. R. Fair, W. D. W. Heston, and C. Cordon-Cardo, “Prostate-specific membrane antigen expression in normal and malignant human tissues,” Clinical Cancer Research, vol. 3, no. 1, pp. 81–85, 1997. View at Google Scholar · View at Scopus
  14. C. Kratochwil, F. L. Giesel, M. Stefanova et al., “PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617,” Journal of Nuclear Medicine, vol. 57, no. 8, pp. 1170–1176, 2016. View at Publisher · View at Google Scholar
  15. R. P. Baum, H. R. Kulkarni, C. Schuchardt et al., “177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy,” Journal of Nuclear Medicine, vol. 57, no. 7, pp. 1006–1013, 2016. View at Publisher · View at Google Scholar
  16. G. J. Kelloff, P. Choyke, and D. S. Coffey, “Challenges in clinical prostate cancer: role of imaging,” American Journal of Roentgenology, vol. 192, no. 6, pp. 1455–1470, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Lambin, E. Rios-Velazquez, R. Leijenaar et al., “Radiomics: extracting more information from medical images using advanced feature analysis,” European Journal of Cancer, vol. 48, no. 4, pp. 441–446, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Rajinikanth, M. Manoharan, C. T. Soloway, F. J. Civantos, and M. S. Soloway, “Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years,” Urology, vol. 72, no. 1, pp. 177–182, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Maio, A. Covre, E. Fratta et al., “Molecular pathways: at the crossroads of cancer epigenetics and immunotherapy,” Clinical Cancer Research, vol. 21, no. 18, pp. 4040–4047, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. A. J. Christiansen, A. West, K.-M. Banks et al., “Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 10, pp. 4141–4146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. P. A. Jones and S. B. Baylin, “The fundamental role of epigenetic events in cancer,” Nature Reviews Genetics, vol. 3, no. 6, pp. 415–428, 2002. View at Google Scholar · View at Scopus
  22. G. Egger, G. Liang, A. Aparicio, and P. A. Jones, “Epigenetics in human disease and prospects for epigenetic therapy,” Nature, vol. 429, no. 6990, pp. 457–463, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. Z. Kote-Jarai, C. Mikropoulos, D. A. Leongamornlert et al., “Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes,” Annals of Oncology, vol. 26, no. 4, pp. 756–761, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Ren, C. Li, W. Duan et al., “MicroRNA-613 represses prostate cancer cell proliferation and invasion through targeting Frizzled7,” Biochemical and Biophysical Research Communications, vol. 469, no. 3, pp. 633–638, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. K. D. Robertson, “DNA methylation and chromatin—unraveling the tangled web,” Oncogene, vol. 21, no. 35, pp. 5361–5379, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. L.-C. Li, P. R. Carroll, and R. Dahiya, “Epigenetic changes in prostate cancer: implication for diagnosis and treatment,” Journal of the National Cancer Institute, vol. 97, no. 2, pp. 103–115, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. D. E. Linn, K. L. Penney, R. T. Bronson, L. A. Mucci, and Z. Li, “Deletion of interstitial genes between TMPRSS2 and ERG promotes prostate cancer progression,” Cancer Research, vol. 76, no. 7, pp. 1869–1881, 2016. View at Publisher · View at Google Scholar
  28. M. Chu, Y. Chang, N. Wang, W. Li, P. Li, and W.-Q. Gao, “Hypermethylation-mediated transcriptional repression of TMPRSS2 in androgen receptor-negative prostate cancer cells,” Experimental Biology and Medicine, vol. 239, no. 7, pp. 823–828, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. B. G. Barwick, M. Abramovitz, M. Kodani et al., “Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts,” British Journal of Cancer, vol. 102, no. 3, pp. 570–576, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. A. Tomlins, B. Laxman, S. Varambally et al., “Role of the TMPRSS2-ERG gene fusion in prostate cancer,” Neoplasia, vol. 10, no. 2, pp. 177–188, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. S. A. Tomlins, D. R. Rhodes, S. Perner et al., “Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer,” Science, vol. 310, no. 5748, pp. 644–648, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Zelic, V. Fiano, C. Grasso et al., “Global DNA hypomethylation in prostate cancer development and progression: a systematic review,” Prostate Cancer and Prostatic Diseases, vol. 18, no. 1, pp. 1–12, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Kinoshita, Y. Shi, C. Sandefur et al., “Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer,” Cancer Research, vol. 60, no. 13, pp. 3623–3630, 2000. View at Google Scholar · View at Scopus
  34. D. K. Mishra, Z. Chen, Y. Wu, M. Sarkissyan, H. P. Koeffler, and J. V. Vadgama, “Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells,” Molecular Cancer Therapeutics, vol. 9, no. 1, pp. 33–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. M. Pomerantz, F. Li, D. Y. Takeda et al., “The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis,” Nature Genetics, vol. 47, no. 11, pp. 1346–1351, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Chen, P. Chi, S. Rockowitz et al., “ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss,” Nature Medicine, vol. 19, no. 8, pp. 1023–1029, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. K.-I. Takayama, A. Misawa, T. Suzuki et al., “TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression,” Nature Communications, vol. 6, article 8219, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. X.-J. Yang and E. Seto, “Lysine acetylation: codified crosstalk with other posttranslational modifications,” Molecular Cell, vol. 31, no. 4, pp. 449–461, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Ringrose and R. Paro, “Epigenetic regulation of cellular memory by the polycomb and trithorax group proteins,” Annual Review of Genetics, vol. 38, pp. 413–443, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Varambally, S. M. Dhanasekaran, M. Zhou et al., “The polycomb group protein EZH2 is involved in progression of prostate cancer,” Nature, vol. 419, no. 6907, pp. 624–629, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. P. L. Clermont, D. Lin, F. Crea et al., “Polycomb-mediated silencing in neuroendocrine prostate cancer,” Clinical Epigenetics, vol. 7, article 40, 2015. View at Google Scholar
  42. G. P. Souroullas, W. R. Jeck, J. S. Parker et al., “An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation,” Nature Medicine, vol. 22, no. 6, pp. 632–640, 2016. View at Publisher · View at Google Scholar
  43. L. Jiao and X. Liu, “Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2,” Science, vol. 350, no. 6258, article aac4383, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Xu, Z. J. Wu, A. C. Groner et al., “EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent,” Science, vol. 338, no. 6113, pp. 1465–1469, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Gu, S. C. Frommel, C. C. Oakes et al., “BAZ2A (TIP5) is involved in epigenetic alterations in Prostate cancer and its overexpression predicts disease recurrence,” Nature Genetics, vol. 47, no. 1, pp. 22–30, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Qi, K. Nakayama, R. D. Cardiff et al., “Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors,” Cancer Cell, vol. 18, no. 1, pp. 23–38, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Li, S. S. Dhar, T. Y. Chen et al., “JARID1D is a suppressor and prognostic marker of prostate cancer invasion and metastasis,” Cancer Research, vol. 76, no. 4, pp. 831–843, 2016. View at Publisher · View at Google Scholar
  48. J. Sayegh, J. Cao, M. R. Zou et al., “Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen,” Journal of Biological Chemistry, vol. 288, no. 13, pp. 9408–9417, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. S. T. Reis, J. Pontes-Junior, A. A. Antunes et al., “miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer,” BMC Urology, vol. 12, no. 1, article 14, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. S. E. Jalava, A. Urbanucci, L. Latonen et al., “Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer,” Oncogene, vol. 31, no. 41, pp. 4460–4471, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Kaneko, R. Bonasio, R. Saldaña-Meyer et al., “Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin,” Molecular Cell, vol. 53, no. 2, pp. 290–300, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. S. N. Kamdar, L. T. Ho, K. J. Kron et al., “Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis,” Clinical Epigenetics, vol. 8, article 32, 2016. View at Publisher · View at Google Scholar
  53. U. Lo, D. Yang, and J. Hsieh, “The role of microRNAs in prostate cancer progression,” Translational Andrology and Urology, vol. 2, no. 3, pp. 228–241, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. Q. Zhang, S. K. R. Padi, D. J. Tindall, and B. Guo, “Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31,” Cell Death and Disease, vol. 5, no. 10, article e1486, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Cao, Z. Deng, M. Wan et al., “MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β,” Molecular Cancer, vol. 9, no. 1, article 108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. M. R. M. Roduan, N. Mohtarrudin, C. P. Pei, M. Osman, and N. M. Dusa, “High expression of cyclooxygenase-2 in high grade human prostate adenocarcinoma,” Sains Malaysiana, vol. 44, no. 5, pp. 727–733, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. W. Qin, Y. Shi, B. Zhao et al., “miR-24 regulates apoptosis by targeting the Open Reading Frame (ORF) region of FAF1 in cancer cells,” PLoS ONE, vol. 5, no. 2, article e9429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Zhao, X. Ye, L. Xiao et al., “MiR-26a inhibits prostate cancer progression by repression of Wnt5a,” Tumor Biology, vol. 35, no. 10, pp. 9725–9733, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Qu, W. Li, M. R. Hellem et al., “MiR‐182 and miR‐203 induce mesenchymal to epithelial transition and self‐sufficiency of growth signals via repressing SNAI2 in prostate cells,” International Journal of Cancer, vol. 133, no. 3, pp. 544–555, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. X. Peng, W. Guo, T. Liu et al., “Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT,” PLoS ONE, vol. 6, no. 5, article e20341, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. N. Bhatnagar, X. Li, S. K. R. Padi, Q. Zhang, M.-S. Tang, and B. Guo, “Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells,” Cell Death & Disease, vol. 1, no. 12, article e105, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Chen, M. S. Zaman, G. Deng et al., “MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer,” Cancer Prevention Research, vol. 4, no. 1, pp. 76–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Chiyomaru, S. Yamamura, S. Fukuhara et al., “Genistein up-regulates tumor suppressor MicroRNA-574-3p in prostate cancer,” PLoS ONE, vol. 8, no. 3, Article ID e58929, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. X. Wang, H. Gao, L. Ren, J. Gu, Y. Zhang, and Y. Zhang, “Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer,” BMC Cancer, vol. 14, no. 1, article 308, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. D. Karan, J. Thrasher, and D. Lubaroff, “Prostate cancer: genes, environment, immunity and the use of immunotherapy,” Prostate Cancer and Prostatic Diseases, vol. 11, no. 3, pp. 230–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. C. F. Heyns, M. Fisher, A. Lecuona, and A. van der Merwe, “Prostate cancer among different racial groups in the western cape: presenting features and management,” South African Medical Journal, vol. 101, no. 4, pp. 267–270, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. B. Kwabi-Addo, W. Chung, L. Shen et al., “Age-related DNA methylation changes in normal human prostate tissues,” Clinical Cancer Research, vol. 13, no. 13, pp. 3796–3802, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Yuan, Y. Jiao, S. de Jong, R. A. Ophoff, S. Beck, and A. E. Teschendorff, “An integrative multi-scale analysis of the dynamic DNA methylation landscape in aging,” PLoS Genetics, vol. 11, no. 2, Article ID e1004996, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Jung, S. Kadam, W. Xiong, T. A. Rauch, S.-G. Jin, and G. P. Pfeifer, “MIRA-seq for DNA methylation analysis of CpG islands,” Epigenomics, vol. 7, no. 5, pp. 695–706, 2015. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Jung and G. P. Pfeifer, “Aging and DNA methylation,” BMC Biology, vol. 13, no. 1, 2015. View at Publisher · View at Google Scholar
  71. N. Mofolo, O. Betshu, O. Kenna et al., “Knowledge of prostate cancer among males attending a urology clinic, a South African study,” SpringerPlus, vol. 4, article 67, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. Y.-Y. Xia, Y.-B. Ding, X.-Q. Liu et al., “Racial/ethnic disparities in human DNA methylation,” Biochimica et Biophysica Acta-Reviews on Cancer, vol. 1846, no. 1, pp. 258–262, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. J. M. Devaney, S. Wang, P. Furbert-Harris et al., “Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men,” Epigenetics, vol. 10, no. 4, pp. 319–328, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Bjartell, “Genetic markers and the risk of developing prostate cancer,” European Urology, vol. 60, no. 1, pp. 29–31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. E. Castro and R. Eeles, “The role of BRCA1 and BRCA2 in prostate cancer,” Asian Journal of Andrology, vol. 14, no. 3, pp. 409–414, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. N. Rivlin, R. Brosh, M. Oren, and V. Rotter, “Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis,” Genes & Cancer, vol. 2, no. 4, pp. 466–474, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. C. E. Barbieri, C. H. Bangma, A. Bjartell et al., “The mutational landscape of prostate cancer,” European Urology, vol. 64, no. 4, pp. 567–576, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Cavanagh and K. M. A. Rogers, “The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers,” Hereditary Cancer in Clinical Practice, vol. 13, no. 1, article 16, pp. 1–7, 2015. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Rosty, M. D. Walsh, N. M. Lindor et al., “High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry,” Familial Cancer, vol. 13, no. 4, pp. 573–582, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Peto, “Cancer epidemiology in the last century and the next decade,” Nature, vol. 411, no. 6835, pp. 390–395, 2001. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Shimizu, R. K. Ross, L. Bernstein, R. Yatani, B. E. Henderson, and T. M. Mack, “Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County,” British Journal of Cancer, vol. 63, no. 6, pp. 963–966, 1991. View at Publisher · View at Google Scholar · View at Scopus
  82. M. D. Lloyd, M. Yevglevskis, G. L. Lee, P. J. Wood, M. D. Threadgill, and T. J. Woodman, “α-methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S,” Progress in Lipid Research, vol. 52, no. 2, pp. 220–230, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Liu, “Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer,” Prostate Cancer and Prostatic Diseases, vol. 9, no. 3, pp. 230–234, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. L. J. Gudas and J. A. Wagner, “Retinoids regulate stem cell differentiation,” Journal of Cellular Physiology, vol. 226, no. 2, pp. 322–330, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. A. P. Bracken and K. Helin, “Polycomb group proteins: navigators of lineage pathways led astray in cancer,” Nature Reviews Cancer, vol. 9, no. 11, pp. 773–784, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Hirata, K. Ueno, K. Nakajima et al., “Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells,” British Journal of Cancer, vol. 108, no. 10, pp. 2070–2078, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. I. Naldi, M. Taranta, L. Gherardini et al., “Novel epigenetic target therapy for prostate cancer: a preclinical study,” PLoS ONE, vol. 9, no. 5, Article ID e98101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. I. Graça, E. J. Sousa, T. Baptista et al., “Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells,” Current Pharmaceutical Design, vol. 20, no. 11, pp. 1803–1811, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Karahoca and R. L. Momparler, “Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′- deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy,” Clinical Epigenetics, vol. 5, no. 1, article 3, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Hagelgans, M. Menschikowski, S. Fuessel et al., “Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms,” Experimental and Molecular Pathology, vol. 94, no. 3, pp. 458–465, 2013. View at Publisher · View at Google Scholar · View at Scopus
  91. B. Fialova, K. S. Trtkova, L. Paskova, K. Langova, and Z. Kolar, “Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines,” Oncology Reports, vol. 29, no. 5, pp. 2039–2045, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. S. K. Kulp, C. S. Chen, D. S. Wang, C. Y. Chen, and C. S. Chen, “Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer,” Clinical Cancer Research, vol. 12, no. 17, pp. 5199–5206, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. L. M. Butler, D. B. Agus, H. I. Scher et al., “Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo,” Cancer Research, vol. 60, no. 18, pp. 5165–5170, 2000. View at Google Scholar · View at Scopus
  94. A. Laurenzana, M. Balliu, C. Cellai, M. N. Romanelli, and F. Paoletti, “Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells,” PLoS ONE, vol. 8, no. 3, Article ID e58267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. N. Patra, U. De, T. H. Kim et al., “A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells,” Biomedicine and Pharmacotherapy, vol. 67, no. 5, pp. 407–415, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. V. Lakshmikanthan, I. Kaddour-Djebbar, R. W. Lewis, and M. V. Kumar, “SAHA-sensitized prostate cancer cells to TNFα-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis,” International Journal of Cancer, vol. 119, no. 1, pp. 221–228, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. R. L. VanOosten, J. K. Earel Jr., and T. S. Griffith, “Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity,” Apoptosis, vol. 12, no. 3, pp. 561–571, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. C. Yu, S. Pan, S. Chao et al., “A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I,” Biochemical Pharmacology, vol. 90, no. 3, pp. 320–330, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. I. A. Asangani, V. L. Dommeti, X. Wang et al., “Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer,” Nature, vol. 510, no. 7504, pp. 278–282, 2014. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Wyce, Y. Degenhardt, Y. Bai et al., “Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer,” Oncotarget, vol. 4, no. 12, pp. 2419–2429, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. F. Crea, E. M. Hurt, L. A. Mathews et al., “Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer,” Molecular Cancer, vol. 10, article 40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. K. F. Schaarschuch, Co-Regulators of Androgen Receptor Transcriptional Activity as a Novel Therapeutic Target for Advanced Prostate Cancer, 2014.
  103. S. R. Daigle, E. J. Olhava, C. A. Therkelsen et al., “Potent inhibition of DOT1L as treatment of MLL-fusion leukemia,” Blood, vol. 122, no. 6, pp. 1017–1025, 2013. View at Publisher · View at Google Scholar · View at Scopus
  104. E. Olhava, R. Chesworth, K. Kuntz, V. Richon, R. Pollock, and S. Daigle, “Preparation of substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes,” PCT Int.Appl.WO, 2011
  105. A. Basavapathruni, E. J. Olhava, S. R. Daigle et al., “Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor,” Biopharmaceutics and Drug Disposition, vol. 35, no. 4, pp. 237–252, 2014. View at Publisher · View at Google Scholar · View at Scopus
  106. W. Yu, E. J. Chory, A. K. Wernimont et al., “Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors,” Nature Communications, vol. 3, article 1288, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. Y. Yao, P. Chen, J. Diao et al., “Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies,” Journal of the American Chemical Society, vol. 133, no. 42, pp. 16746–16749, 2011. View at Publisher · View at Google Scholar · View at Scopus